Publications by authors named "Dominik Zalewski"
Article Synopsis
- This study evaluated the effectiveness of a biosimilar drug, QL1205, compared to the established drug ranibizumab (Lucentis®) in patients with neovascular age-related macular degeneration (nAMD) through a rigorous phase 3 trial.* -
- A total of 616 treatment-naïve patients were randomly assigned to receive either QL1205 or ranibizumab, and both groups were given injections every four weeks for 48 weeks, with the main focus on changes in best-corrected visual acuity (BCVA).* -
- Results showed similar improvements in visual acuity for both QL1205 (+6.3 letters) and ranibizumab (+7.
Introduction: SB11 (Byooviz™; Samsung Bioepis Co., Ltd.) is a ranibizumab (Lucentis; Genentech, Inc.
View Article and Find Full Text PDFArticle Synopsis
- This study aimed to evaluate the long-term efficacy, safety, immunogenicity, and pharmacokinetics of the ranibizumab biosimilar SB11 compared to the original ranibizumab (RBZ) in patients with neovascular age-related macular degeneration (nAMD).
- Conducted as a multicenter, randomized, double-masked, parallel-group phase III equivalence trial with 705 participants, the study involved monthly intravitreal injections of either SB11 or RBZ and followed participants for 52 weeks.
- Results showed comparable visual outcomes, safety profiles, and immune responses between SB11 and RBZ, confirming that SB11 is a suitable alternative to RBZ in treating nAMD.
Article Synopsis
- Neovascular age-related macular degeneration is a major cause of blindness in people over 50, and the ranibizumab biosimilar (SB11) could provide a more accessible treatment option.
- A phase 3 study involving 705 participants was conducted across 75 centers in multiple countries to compare the efficacy, safety, and immunogenicity of SB11 to the reference drug ranibizumab.
- Results showed that the visual acuity and central subfield thickness improvements were similar between the two treatments, indicating that SB11 is a viable alternative to ranibizumab.
The diagnosis and treatment of diabetic retinopathy (DR) in young adults have significantly improved in recent years. Research methods have widened significantly, for example, by introducing spectral optical tomography of the eye. Invasive diagnostics, for example, fluorescein angiography, are done less frequently.
View Article and Find Full Text PDFAims: This retrospective analysis was aimed at evaluating the effectiveness of treatment of persistent diabetic macular edema with intravitreal injections of 0.7 mg dexamethasone implant Ozurdex. The study comprised three male patients (6 eyes).
View Article and Find Full Text PDF